Indoco Remedies receives EIR from USFDA

Alembic Pharmaceuticals on Tuesday said it has received final approval from the US health regulator for its generic Silodosin capsules used in treatment of benign prostatic hyperplasia. The approval by the US Food and Drug Administration (USFDA) for Silodosin capsules is for multiple strengths of 4 mg and 8 mg, the company said in a regulatory filing. It is therapeutically equivalent to the reference listed drug product Rapaflo Capsules, 4 mg and 8 mg, of Allergan Sales, LLC, it added. Silodosin capsule is indicated for treatment of the signs and symptoms of benign prostatic hyperplasia. Citing IQVIA data, the company said Silodosin capsules have an estimated market size of USD 114 million for 12-months ending June 2019. Alembic now has a total of 108 ANDA approvals (96 final approvals and 12 tentative approvals) from USFDA, the company said.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001248 seconds